A meta-analysis of TET2 mutations shows a distinct distribution pattern in de novo acute myeloid leukemia and chronic myelomonocytic leukemia

Leukemia and Lymphoma

Volumn 53, Issue 6, 2012, Pages 1230-1233

  Euba, Begoña ^a   Vizmanos, José L ^a   García Granero, Marta ^a   Aranaz, Paula ^a   Hurtado, Cristina ^a   Migueliz, Itziar ^a   Novo, Francisco J ^a   García Delgado, Marina ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; CHROMOSOME 4Q; CHRONIC MYELOMONOCYTIC LEUKEMIA; EXON; GENE; GENE FREQUENCY; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; LETTER; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; TET2 GENE;

AGE OF ONSET; DNA-BINDING PROTEINS; GENE FREQUENCY; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MUTATION; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; PROTO-ONCOGENE PROTEINS;

EID: 84861389471     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.639878     Document Type: Letter

References (15)

1. Martin C, Leroy G, Delhommeau F, et al. Analysis of the Ten-Eleven Translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood 2009;114:1628-1632.
2. Szpurka H., Jankowska AM, Makishima H, et al. Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations. Leuk Res 2010;34:969-973.
3. Nibourel O, Kosmider O, Cheok M, et al. Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood 2010;116:1132-1135.
4. Kohlmann A, Grossmann V, Klein H-U, et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol 2010;28:3858-3865.
5. Colaizzo D, Tiscia GL, Pisanelli D, et al. New TET2 gene mutations in patients with myeloproliferative neoplasms and splanchnic vein thrombosis. J Th romb Haemost 2010;8:1142-1144.
6. Rocquain J, Carbuccia N, Trouplin V, et al. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer 2010;10:401.
7. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010;24:1128-1138.
8. Abdel-Wahab O, Manshouri T, Patel J, et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 2010;70:447-452.
9. Smith AE, Mohamedali AM, Kulasekararaj A, et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low abundance mutant clones with early origins, but indicates no defi nite prognostic value. Blood 2010;116:3923-3932.
10. Ko M, Huang Y, Jankowska AM, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010;468:839-843.
11. Pollyea DA, Raval A, Kusler B, et al. Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors. Hematol Oncol 2011;29:157-160.
12. Bacher U, Haferlach C, Schnittger S, et al. Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies. Ann Hematol 2010;89:643-652.
13. Metzeler KH, Maharry K, Radmacher MD, et al. TET2 mutations improve the new European LeukemiaNet risk classifi cation of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2011;29:1373-1381.
14. Tahiliani M, Koh KP, Shen Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009;324:930-935.
15. Holmfeldt L, Mullighan CG. The role of TET2 in hematologic neoplasms. Cancer Cell 2011;20:1-2.